{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-24-000137","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.243170+00:00","generated_at":"2026-06-02T22:41:15.126679+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex Q1 product revenue $2.69B (+13% YoY); reiterates FY guidance; $4.9B Alpine acquisition","bullets":["Q1 product revenue $2.69B, up 13% YoY; GAAP net income up 57%; Non-GAAP net income up 56%.","Reiterates FY2024 product revenue guidance $10.55-$10.75B; combined non-GAAP R&D and SG&A $4.3-$4.4B.","Submitted NDA (priority review) for vanzacaftor triple in CF to FDA and MAA to EMA; rolling NDA for suzetrigine in acute pain.","Entered agreement to acquire Alpine Immune Sciences for ~$4.9B ($65/sh cash); expected close Q2 2024.","Cash and marketable securities $14.6B; >25 CASGEVY ATCs activated globally; multiple patients started cell collection."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-24-000137","json":"https://secwatch.observer/filing/0000875320-24-000137.json","markdown":"https://secwatch.observer/filing/0000875320-24-000137.md","text":"https://secwatch.observer/filing/0000875320-24-000137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/vrtx-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T22:41:15.126679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c8ae160abdb1cd9eab62155f5c26fbb5d99dd06","claim":"VERTEX PHARMACEUTICALS INC / MA reported full year 2024 results: revenue 10.55 to 10.75 billion. Guidance reaffirmed.","evidence_excerpt":"Vertex today reiterated its full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2024"},{"label":"Revenue","value":"10.55 to 10.75 billion"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}]},{"claim_id":"fe196d352ae4ab17c9184ddbd2e638b6c6f2cfc0","claim":"VERTEX PHARMACEUTICALS INC / MA reported first quarter ended March 31, 2024 results: revenue 2.69 billion.","evidence_excerpt":"as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% i ncrease compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000137/0000875320-24-000137-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"2.69 billion"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}